Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Elucidating the therapeutic potential of targeting aryl hydrocarbon receptors in macrophages in pancreatic ductal adenocarcinoma to improve immunotherapy

FY 2019-20

Summary
"Pancreatic ductal adenocarcinoma (PDAC) is a malignant cancer of the pancreas and has the lowest 5-year patient survival rate of all major cancer types. Cancer immunotherapy is an increasingly popular and promising approach to treating cancer patients. Immunotherapy is founded on our understanding of how cytotoxic lymphocytes (CTLs), a type of cells of our own immune system can recognize and eradicate cancerous cells. Immunotherapy takes advantage of this knowledge by, for instance, boosting our CTLs to kill tumour cells. However, this approach has shown limited success in PDAC, which can be attributed to the immunosuppressive cells that inhibit the CTLs from killing the tumour cells through various mechanisms. One of such immunosuppressive cells are tumour-associated macrophages (TAMs), which have found to be associated with poor prognosis in PDAC. To overcome this obstacle in immunotherapy, we can target these immunosuppressive TAMs to enhance tumour eradication by CTLs. Interestingly, we have found that a receptor molecule in TAMs, the aryl hydrocarbon receptor (AhR), regulates the expression of inhibitory molecules that are inhibitory signals for CTLs to reduce killing of tumours. Thus, this project proposes to investigate how we can target AhR to reduce immunosuppression, enhance eradication of tumour cells by CTLs, and ultimately increase survival in PDAC patients."
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428966
Name
Liu Zhe Qi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the therapeutic potential of targeting aryl hydrocarbon receptors in macrophages in pancreatic ductal adenocarcinoma to improve immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Cyototoxic T Lymphocytes; Immunosuppression; Immunotolerance; Macrophages; Pancreatic Ductal Adenocarcinoma; Therapeutic Validation; Tumour Microenvironment
Abstract
"Pancreatic ductal adenocarcinoma (PDAC) is a malignant cancer of the pancreas and has the lowest 5-year patient survival rate of all major cancer types. Cancer immunotherapy is an increasingly popular and promising approach to treating cancer patients. Immunotherapy is founded on our understanding of how cytotoxic lymphocytes (CTLs), a type of cells of our own immune system can recognize and eradicate cancerous cells. Immunotherapy takes advantage of this knowledge by, for instance, boosting our CTLs to kill tumour cells. However, this approach has shown limited success in PDAC, which can be attributed to the immunosuppressive cells that inhibit the CTLs from killing the tumour cells through various mechanisms. One of such immunosuppressive cells are tumour-associated macrophages (TAMs), which have found to be associated with poor prognosis in PDAC. To overcome this obstacle in immunotherapy, we can target these immunosuppressive TAMs to enhance tumour eradication by CTLs. Interestingly, we have found that a receptor molecule in TAMs, the aryl hydrocarbon receptor (AhR), regulates the expression of inhibitory molecules that are inhibitory signals for CTLs to reduce killing of tumours. Thus, this project proposes to investigate how we can target AhR to reduce immunosuppression, enhance eradication of tumour cells by CTLs, and ultimately increase survival in PDAC patients."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liu, Zhe Qi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~